Endorsed NICE Technology Appraisals 2008/2009
Date published:
Endorsed NICE Technology Appraisals 2008/2009
The following NICE Technology Appraisals were endorsed by DoH during 2008-09
Documents
- National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA103 - Psoriasis - Efalizumab and Etarnercept - HSC(SQSD) (NICE) 21/2009
- National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA123 - Varenicline for Smoking Cessation - HSC(SQSD) (NICE) 21/2008
- National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA124 - Pemetrexed for Non-small Cell Lung Cancer - HSC (SQSD) (NICE) 22/2008
- Technology Appraisal No 181 – Pemetrexed for the First-Line Treatment of Non- Small- Cell Lung Cancer - HSC (SQSD) (NICE) 19/2010
- National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA131 - Inhaled corticosteroids for the treatment of chronic asthma in children under the age of 12 years - HSC (SQSD) (NICE) 30/2008
- National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA134 - Infliximab for the treatment of adults with psoriasis - HSC (SQSD) (NICE) 31/2008
- National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA136 - Structural Neuroimaging in first onset psychosis - HSC (SQSD) (NICE) 32/2008
- National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA137 - Rituximab for the treatment of relapsed or refractory stage iii or Stage iv follicular Non-Hodgkin’s lymphoma - HSC (SQSD) (NICE) 56/2008
- National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA138 - Corticosteroids for the treatment of chronic asthma in adults and children aged 12 years and over - HSC (SQSD) (NICE) 10/2009
- National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA139 - Continuous Positive Airway Pressure (CPAP) for the treatment of Obstructive Sleep Apnoea/Hypopnoea Syndrome (OSAHS) - HSC (SQSD) (NICE) 57/2008
- National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA140 - Infliximab for the treatment of ulcerative colitis - HSC (SQSD) (NICE) 01/2009
- National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA142 - Erythropoietin (alpha and beta) and darbepoetin for the treatment of cancer -treatment induced anaemia - HSC (SQSD) (NICE) 11/2009
- National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA145 - Cetuximab for the treatment of head and neck cancer - HSC (SQSD) (NICE) 03/2009
- National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA146 - Adalimumab for the treatment of psoriasis - HSC (SQSD) (NICE) 04/2009
- National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA155 - Pegaptanib and Ranibizumab for age-related macular degeneration - HSC (SQSD) (NICE) 53/2008
- National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA156 - Pregnancy - Routine antenatal Anti-D Prophylaxis for women who are Rhesus D negative - HSC (SQSD) (NICE) 54/2008
- National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA159 - Spinal cord stimulation for chronic pain of neuropathic or ischaemic origin - HSC (SQSD) (NICE) 16/2009